tiprankstipranks
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
US Market
MAZE
Maze Therapeutics, Inc.
RESEARCH TOOLSreports

Maze Therapeutics, Inc. (MAZE) Stock News & Sentiment

Compare
74 Followers
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
Premium
Ratings
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829
3d ago
MAZE
Maze Therapeutics adds Neil Kumar to board leadership
Premium
Company Announcements
Maze Therapeutics adds Neil Kumar to board leadership
4d ago
8K
MAZE
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
Premium
Ratings
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE
20d ago
MAZE
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
Premium
Ratings
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside
24d ago
MAZE
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
Premium
Ratings
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst
1M ago
MAZE
Maze Therapeutics Secures New $200 Million Loan Facility
Premium
Company Announcements
Maze Therapeutics Secures New $200 Million Loan Facility
2M ago
8K
MAZE
Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target
Premium
Ratings
Buy Rating on Maze Therapeutics: Attractive Risk‑Reward Driven by Differentiated APOL1 Kidney Disease Therapy MZE829 and Raised $46 Target
2M ago
MAZE
More MAZE News >

MAZE News on the Web

Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital
TipRanks News
Neutral
Weekly Buzz: CORT Wins FDA Nod In Cancer; MRK Acquires TERN; INSM Meets Trial Goals But VALN Misses
rttnews
Bullish
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
Zacks
Bullish
Analysts Conflicted on These Healthcare Names: Maze Therapeutics, Inc. (MAZE), Azitra Inc (AZTR) and Arrowhead Pharmaceuticals (ARWR)
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Zai Lab (ZLAB), Maze Therapeutics, Inc. (MAZE) and Compass Therapeutics (CMPX)
TipRanks News
Bullish
Wedbush Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
TipRanks News
Neutral
Maze Therapeutics' Positive Phase 2 Data and $360M Cash Runway Highlight Strong Foundation for Kidney and Metabolic Disease Pipeline
Market Chameleon
Neutral
Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Maze Therapeutics, Inc. (MAZE)
TipRanks News
Bullish

News Score - Last 7 Days

Positive
MAZE
Sector Average
Media Buzz
This Week30 articles
Weekly Average11.25 articles
News Sentiment
This Week77%
Sector Average67%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MAZE’s Media Buzz Sentiment?
30 articles about MAZE were published this week. In an average week, 11.25 articles are published.
    What is MAZE’s weekly average amount of articles?
    In an average week, 11.25 articles about MAZE are published.
      What is MAZE’s News Sentiment?
      77% of articles about MAZE were positive this week, compared to its sector average of 67%.
        Healthcare Stocks that are Trending in the News
        PYXSPyxis Oncology
        WXIBFWuxi Biologics (Cayman)
        KODKodiak Sciences
        SHTDYSinopharm Group Co
        GILDGilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S
        Showing the stocks with the most bullish news sentiment over the past week